Quantum BioPharma Sets Record Date for Litigation-Linked CVR Distribution

Quantum BioPharma Ltd. has announced October 27, 2025 as the record date for the distribution of contingent value rights to holders of its Class B Subordinate Voting Shares on a one-for-one basis. Each CVR entitles holders to a pro rata portion of between 10% and 50% of any net proceeds ultimately recovered from the company's ongoing litigation against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million. The CVRs are non-transferable, carry no interest or voting rights, and will only be redeemable for cash if Qualifying Net Proceeds are received through settlement or a final, non-appealable judgment.

The distribution represents a significant development for shareholders who could potentially benefit from the substantial litigation proceeds if the company prevails in its legal action. The litigation targets major financial institutions, indicating the scale and importance of the legal battle. The CVR structure provides shareholders with direct exposure to the litigation outcome while maintaining their existing equity positions in the company. This approach allows investors to participate in potential upside from the legal proceedings without additional investment requirements.

Quantum BioPharma's decision to issue CVRs tied to litigation outcomes reflects a growing trend among companies seeking to monetize legal claims while providing value to shareholders. The specific percentage range of 10% to 50% of net proceeds suggests the company has structured the distribution to balance shareholder compensation with retaining sufficient funds for ongoing operations and future development. The non-transferable nature of the CVRs means shareholders must maintain their positions to benefit from any potential recovery, potentially providing stability to the company's shareholder base during the litigation process.

The record date establishment marks a critical milestone in the company's corporate strategy and provides clarity to investors regarding their potential entitlement to litigation proceeds. Shareholders of record on October 27, 2025 will be eligible to receive the CVRs, which represent a novel form of value distribution tied specifically to the outcome of the company's legal proceedings. The full details of the distribution and litigation can be found in the official press release available at https://ibn.fm/P9Wrt. This development underscores the company's commitment to maximizing shareholder value through various corporate initiatives, including strategic litigation that could significantly impact the company's financial position if successful.